ARCHIVED


7.01.10ARCHIVADA ARTROPLASTIA DE CADERA POR METODO MINIMAMENTE INVASIVO
SecciónCirugía Fecha Original: 1 de octubre de 2004
SubsecciónCirugía Fecha Revisión16 de mayo de 2016
“Esta política está protegida por derechos de autor bajo las leyes federales y/o las leyes de propiedad intelectual y las de regulaciones estatales. Ninguna parte de esta publicación puede ser reproducida, almacenada en un sistema de recuperación, transmitida en cualquier forma o por cualquier medio, sea electrónico, mecánico, fotocopia, grabación o cualquier otro, sin el permiso escrito del plan de salud.”

Definición


La operación clásica para reparar una fractura de cadera envuelve un abordaje anterolateral o posterolateral con una incisión de 25-30 cms de largo. Esta técnica provee una exposición continua y completa de la cadera. Esta exposición conlleva trauma considerable a los músculos y tendones, dolor postoperatorio que requiere permanecer en el hospital y dilación en la iniciación de la terapia física postoperatoria. En algunos pacientes este trauma a los tejidos blandos lleva a una debilidad prolongada de la extremidad. Recientemente se ha propuesto una técnica de invasión mínima con incisiones de 10 cms que produce menos dolor y trauma a los músculos, pero a expensa de un campo operatorio con visión limitada. Los sistemas de navegación computarizada pueden utilizarse para facilitar la exposición y la colocación de la prótesis.
La ventaja potencial del método mínimamente invasivo estriba en un tiempo operatorio más corto, estadía hospitalaria más corta, y rápida rehabilitación. Esto frente a mayor dificultad operatoria, visibilidad reducida y espera por el desarrollo de las destrezas de la técnica.
Política
La artroplastia minimamente invasiva para reemplazo de cadera o reemplazo de rodilla se considera para pago cuando se realiza en pacientes adecuadamente seleccionados por cirujanos adecuadamente entrenados y experimentados en las técnicas utilizadas y la institución donde se realiza esta debidamente acreditada con un programa abarcador de rehabilitación postoperatoria.
Se consideran pacientes selectos aquellos que cumplan con los criterios para reemplazo de cadera o rodilla y no son obesos y están motivados a participar en un programa acelerado de rehabilitación.
Códigos
Codes Number Description
CPT 27125 Hemiarthroplasty, hip, partial (e.g., femoral stem prosthesis, bipolar arthroplasty)
27130 Arthroplasty, acetabular and proximal femoral prosthetic replacement (total hip arthroplasty), with or without autograft or allograft
27447 Arthroplasty, knee, condyle and plateau; medial AND lateral compartments with or without patella resurfacing (total knee arthroplasty)
ICD-9 Procedure 81.51 Total hip replacement
81.54 Total knee replacement

Limitación
Según las establecidas en póliza.
___________ ____________________________________
Ángela Hernández, MD Enid M. Mateo Reyes, MD
Director Médico Asociado Director Médico Asociado
Rev.05/16/16
05/10/2013
05/31/12
07/08/09 (iCES)
01/16/06

Referencias

  • Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Cryoablation for the primary treatment of clinically localized prostate cancer. TEC Assessments 2001; Volume16, Tab 6.

  • Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Cryosurgery of Prostate (230.9). 2001. Available online at: http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=123&bc=AgAAQAAAAAAA&ncdver=1. Last accessed April 2013.

  • Shelley M, Wilt TJ, Coles B et al. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev 2007; (3):CD005010.

  • Wilt TJ, Shamliyan T, Taylor B et al. Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer. Rockville (MD)2008.

  • Chou R, Dana T, Bougatsos C et al. Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation. Rockville (MD)2011.

  • Grimm P, Billiet I, Bostwick D et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109 Suppl 1:22-9.

  • Chin JL, Ng CK, Touma NJ et al. Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. Prostate Cancer Prostatic Dis 2008; 11(1):40-5.

  • Chin JL, Al-Zahrani AA, Autran-Gomez AM et al. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). J Urol 2012; 188(4):1170-5.

  • Donnelly BJ, Saliken JC, Brasher PM et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010; 116(2):323-30.

  • Robinson JW, Donnelly BJ, Siever JE et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009; 115(20):4695-704.

  • Bahn DK, Lee F, Badalament R et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002; 60(2 Suppl 1):3-11.

  • Donnelly BJ, Saliken JC, Ernst DS et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology 2002; 60(4):645-9.

  • Ellis DS. Cryosurgery as primary treatment for localized prostate cancer: a community hospital experience. Urology 2002; 60(2 Suppl 1):34-9.

  • Long JP, Bahn D, Lee F et al. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001; 57(3):518-23.

  • Onik G. Image-guided prostate cryosurgery: state of the art. Cancer Control 2001; 8(6):522-31.

  • Robinson JW, Donnelly BJ, Saliken JC et al. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 2002; 60(2 Suppl 1):12-8.

  • Aus G, Pileblad E, Hugosson J. Cryosurgical ablation of the prostate: 5-year follow-up of a prospective study. Eur Urol 2002; 42(2):133-8.

  • De La Taille A, Benson MC, Bagiella E et al. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int 2000; 85(3):281-6.

  • Han KR, Cohen JK, Miller RJ et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 2003; 170(4 Pt 1):1126-30.

  • Prepelica KL, Okeke Z, Murphy A et al. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer 2005; 103(8):1625-30.

  • Aus G. Cryosurgery for prostate cancer. J Urol 2008; 180(5):1882-3.

  • Lian H, Guo H, Gan W et al. Cryosurgery as primary treatment for localized prostate cancer. Int Urol Nephrol 2011; 43(4):1089-94.

  • Ball AJ, Gambill B, Fabrizio MD et al. Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. J Endourol 2006; 20(10):723-31.

  • Williams SB, Lei Y, Nguyen PL et al. Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer. BJU Int 2011.

  • Mouraviev V, Spiess PE, Jones JS. Salvage Cryoablation for Locally Recurrent Prostate Cancer Following Primary Radiotherapy. Eur Urol 2012.

  • Wenske S, Quarrier S, Katz AE. Salvage Cryosurgery of the Prostate for Failure After Primary Radiotherapy or Cryosurgery: Long-term Clinical, Functional, and Oncologic Outcomes in a Large Cohort at a Tertiary Referral Centre. Eur Urol 2012 [Epub ahead of print].

  • Ng CK, Moussa M, Downey DB et al. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. J Urol 2007; 178(4 Pt 1):1253-7; discussion 57.

  • Ismail M, Ahmed S, Kastner C et al. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007; 100(4):760-4.

  • Williams AK, Martinez CH, Lu C et al. Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. Eur Urol 2011; 60(3):405-10.

  • Truesdale MD, Cheetham PJ, Hruby GW et al. An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: recommendations for follow up. Cancer J 2010; 16(5):544-9.

  • Bahn DK, Silverman P, Lee F, Sr. et al. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol 2006; 20(9):688-92.

  • Bahn D, de Castro Abreu AL, Gill IS et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012; 62(1):55-63..

  • Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 2011.

  • National Cooperative Cancer Network. Prostate cancer. Clinical Practice Guidelines in Oncology, v.2.2013. Available online at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Last accessed April 2013.

  • Best practice policy statement on cryosurgery for the treatment of localized prostate cancer. American Urological Association Education and Research, Inc. Linthicum (MD): American Urological Association Education and Research, Inc.; 2008. 50 p. Available online at: http://www.auanet.org/content/media/cryosurgery08.pdf. Last accessed April 2013.